Where I see patients (2)
My reviews
Selected research
-
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Blood
-
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
Blood advances
-
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
The New England journal of medicine
Clinical trials
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...
The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multipl...
Safety will be evaluated for the population of participants who received at least one dose of study drug. Treatment-emergent AEs will be graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Recruiting
5.0